India全球化資本 IGC 深 滬
等待開盤 07-02 09:30:00 美东时间
0.2764
+0.004
+1.62%
華盛通- 最 高0.281
- 今 開0.2721
- 成交量 16.66万股
- 最 低 0.272
- 昨 收 0.272
- 總市值 2766.52万
- 52周最高 0.4985
- 市盈率 靜 --
- 換手率 0.17%
- 52周最低 0.242
- 委 比 -50.00%
- 總股本 1.00亿
- 歷史最高 14.58
- 量 比 0.93
- 振 幅 3.31%
- 歷史最低 0.242
- 每 手 1
- 風險率 0.06%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 存储再获看多！美光、闪迪、西部数据获机构上调目标价；次新股Cerebras、Blackstone、EagleRock获多家机构首予买入平均
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5.25美元升至5.5美元；Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从9美元升至9.25美元
06-09 11:33
Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $5.5
Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $5.25 to $5.5.
06-08 17:21
"Marijuana Components Have 'Consistent' Anti-Tumor Effects In Glioblastoma And Other Cancers, Scientific Review Shows" - Marijuana Moment
https://www.marijuanamoment.net/marijuana-components-have-consistent-anti-tumor-effec
05-29 23:13
IGC Pharma Receives Authorization In Colombia To Synthesize, Formulate, And Conduct Development Activities Involving Psilocybin At Its R&D Facility In Bogotá
Authorization provides regulated capability to evaluate emerging therapeutic approaches alongside Phase 2 CALMA trial approaching completionPOTOMAC, MD / ACCESS Newswire / April 20, 2026 / IGC Pharma, Inc. (NYSE:IGC)
04-20 20:33
美股大行评级 | 瑞银上调美光科技目标价从510升至535美元；巴克莱下调Robinhood 目标价从124降至89美元
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从5美元升至5.25美元；Benchmark：维持Direct Digital Holdings"投机性买入"评级，目标价从2美元升至8美元
04-09 10:15
Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $5.25
Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $5 to $5.25.
04-08 17:56
'Medicare CBD Pilot Will Allow Some THC in Products'- Cannabis Wire
https://cannabiswire.com/newsletters/scoop-medicare-cbd-pilot-will-allow-some-thc-in-products/?free_read=1773920530418
03-19 22:30
IGC Pharma Q3 EPS $(0.01) Beats $(0.02) Estimate, Sales $213.000K Miss $325.000K Estimate
IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. This is a 50 percent increase over losses of $(0.02) per share from the same period
03-19 21:25
美股大行评级 | 大摩将康宁目标价从103美元升至127美元；潜在涨幅1779.7%！IGC Pharma获Ascendiant Capital升目标价至5美元
今日重点评级关注：Ascendiant Capital：维持IGC Pharma"买入"评级，目标价从4.75美元升至5美元；Brookline Capital：维持C4 Therapeutics"买入"评级，目标价从20美元升至30美元
02-24 10:27
Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $5
Ascendiant Capital analyst Edward Woo maintains IGC Pharma (AMEX:IGC) with a Buy and raises the price target from $4.75 to $5.
02-23 18:00
